Modular Medical (MODD)


Market Price (11/18/2026): $1.8 | Market Cap: $17.5 MilSector: Health Care | Industry: Life Sciences Tools & Services

Modular Medical (MODD)


Market Price (11/18/2026): $1.8
Market Cap: $17.5 Mil
Sector: Health Care
Industry: Life Sciences Tools & Services

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35%

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Wearable Health Devices, Show more.

Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -163%

Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -27 Mil

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -197%

High stock price volatility
Vol 12M is 142%

Key risks
MODD key risks include [1] potential delays in FDA clearance for its Pivot insulin pump, Show more.

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -35%
1 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Digital Health & Telemedicine. Themes include Diabetes Management, Wearable Health Devices, Show more.
2 Weak multi-year price returns
2Y Excs Rtn is -121%, 3Y Excs Rtn is -163%
3 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
4 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -27 Mil
5 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -197%
6 High stock price volatility
Vol 12M is 142%
7 Key risks
MODD key risks include [1] potential delays in FDA clearance for its Pivot insulin pump, Show more.

MODD in ETFs

Weight = MODD's share of each fund

VTI0.00%

Valuation & Metrics

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Prices as of 11/17/2026

Nov 17: down 5.8% in one day (S&P 500 down 1.0%)
The stock declined without company news. Slower retail sales dragged on the market, which also fell that day.

Up 53.9% from its Nov 5 low to Nov 13, down 8.6% since (S&P 500 up 2.9%)
This period saw the stock rise significantly without company-specific headlines in our feed. The largest daily increase occurred on November 9, with no company news, as the broader market staged a broad-based relief rally; today also contributed a strong gain.

Show more
Prices as of 11/17/2026

Nov 17: down 5.8% in one day (S&P 500 down 1.0%)
The stock declined without company news. Slower retail sales dragged on the market, which also fell that day.

Up 53.9% from its Nov 5 low to Nov 13, down 8.6% since (S&P 500 up 2.9%)
This period saw the stock rise significantly without company-specific headlines in our feed. The largest daily increase occurred on November 9, with no company news, as the broader market staged a broad-based relief rally; today also contributed a strong gain.

Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The -24.7% change in MODD stock from 7/31/2026 to 11/17/2026 was primarily driven by a -58.7% change in the company's Shares Outstanding (Mil).
(LTM values as of)731202611172026Change
Stock Price ($)2.391.80-24.7%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)38-58.7%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2026 to 11/17/2026
ReturnCorrelation
MODD-24.7% 
Market (SPY)-1.7%29.4%
Sector (XLV)14.4%24.6%

Fundamental Drivers

The -58.5% change in MODD stock from 4/30/2026 to 11/17/2026 was primarily driven by a -72.3% change in the company's Shares Outstanding (Mil).
(LTM values as of)430202611172026Change
Stock Price ($)4.341.80-58.5%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)28-72.3%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2026 to 11/17/2026
ReturnCorrelation
MODD-58.5% 
Market (SPY)2.4%31.3%
Sector (XLV)27.9%14.2%

Fundamental Drivers

The -87.9% change in MODD stock from 10/31/2025 to 11/17/2026 was primarily driven by a -77.2% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202511172026Change
Stock Price ($)14.851.80-87.9%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)28-77.2%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 11/17/2026
ReturnCorrelation
MODD-87.9% 
Market (SPY)8.5%24.1%
Sector (XLV)30.6%10.2%

Fundamental Drivers

The -95.3% change in MODD stock from 10/31/2023 to 11/17/2026 was primarily driven by a -92.8% change in the company's Shares Outstanding (Mil).
(LTM values as of)1031202311172026Change
Stock Price ($)38.101.80-95.3%
Change Contribution By: 
Total Revenues ($ Mil)000.0%
P/S Multiple∞∞0.0%
Shares Outstanding (Mil)18-92.8%
Cumulative Contribution0.0%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2023 to 11/17/2026
ReturnCorrelation
MODD-95.3% 
Market (SPY)81.6%19.9%
Sector (XLV)56.4%11.5%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
MODD Return0%733%-9%-25%-73%-84%-75%
Peers Return17%-25%-19%14%-11%-27%-47%
S&P 500 Return27%-19%24%23%16%8%97%

Monthly Win Rates [3]
MODD Win Rate0%58%67%33%17%36% 
Peers Win Rate56%49%40%50%40%43% 
S&P 500 Win Rate75%42%67%75%67%36% 

Max Drawdowns [4]
MODD Max Drawdown0%-64%-72%-47%-78%-92% 
Peers Max Drawdown-26%-47%-53%-34%-40%-54% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: PODD, TNDM, MDT, EMBC.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 11/17/2026 (YTD)

How Low Can It Go

EventMODDS&P 500
2025 US Tariff Shock
  % Loss-32.8%-18.8%
  % Gain to Breakeven48.8%23.1%
  Time to Breakeven17 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-14.9%-9.5%
  % Gain to Breakeven17.4%10.5%
  Time to Breakeven7 days24 days
2023 SVB Regional Banking Crisis
  % Loss-59.3%-6.7%
  % Gain to Breakeven145.9%7.1%
  Time to Breakeven231 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-23.2%-24.5%
  % Gain to Breakeven30.2%32.4%
  Time to Breakeven8 days427 days

Compare to PODD, TNDM, MDT, EMBC

In The Past

Modular Medical's stock fell -32.8% during the 2025 US Tariff Shock. Such a loss loss requires a 48.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventMODDS&P 500
2025 US Tariff Shock
  % Loss-32.8%-18.8%
  % Gain to Breakeven48.8%23.1%
  Time to Breakeven17 days79 days
2023 SVB Regional Banking Crisis
  % Loss-59.3%-6.7%
  % Gain to Breakeven145.9%7.1%
  Time to Breakeven231 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-23.2%-24.5%
  % Gain to Breakeven30.2%32.4%
  Time to Breakeven8 days427 days

Compare to PODD, TNDM, MDT, EMBC

In The Past

Modular Medical's stock fell -32.8% during the 2025 US Tariff Shock. Such a loss loss requires a 48.8% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Modular Medical (MODD)

Modular Medical, Inc. (MODD) is a development-stage medical device company dedicated to creating innovative solutions for the diabetes marketplace. The company's primary focus lies in the design, development, and future commercialization of advanced insulin pumps.

These insulin pumps are being developed with proprietary technology specifically engineered to enhance their adoption among patients with diabetes. The core aim is to make insulin pump therapy more accessible, user-friendly, and effective, ultimately increasing its prevalence and improving patient outcomes in managing their condition.

Modular Medical targets the broad market of individuals living with diabetes who require insulin therapy and could benefit from advanced pump technology. By prioritizing enhanced adoption through innovative design, the company aims to serve a wide range of diabetes patients seeking more convenient and efficient methods for insulin delivery.

AI Analysis | Feedback

Here are 1-3 brief analogies for Modular Medical (MODD):

  • A development-stage competitor to Insulet (Omnipod) in the insulin pump market.
  • An innovative startup aiming to revolutionize insulin pumps, similar to an early Tandem Diabetes Care.

AI Analysis | Feedback

  • Insulin Pumps: Medical devices under development designed to deliver insulin to individuals with diabetes, leveraging technology to enhance pump adoption.

AI Analysis | Feedback

Modular Medical, Inc. (MODD) is a development stage medical device company focused on the design, development, and commercialization of insulin pumps. As a development stage company, it has not yet achieved significant commercial sales and, therefore, does not currently have major customers or generate significant product revenue.

However, upon successful commercialization, Modular Medical's insulin pumps are designed for individuals requiring insulin therapy. Consequently, the primary categories of customers it will serve are expected to be:

  • Individuals with Type 1 Diabetes: Patients who require continuous and precise insulin delivery due to the body's inability to produce insulin.
  • Individuals with Insulin-Dependent Type 2 Diabetes: Patients whose Type 2 diabetes has progressed to a stage requiring insulin therapy and who could benefit from the enhanced glycemic management and flexibility offered by an insulin pump.

AI Analysis | Feedback

null

AI Analysis | Feedback

James (Jeb) Besser, Chief Executive Officer

James (Jeb) Besser is the Chief Executive Officer of Modular Medical. He has been a Managing Member of Manchester Management LLC for 23 years, which is the largest shareholder of Modular Medical, Inc.. Mr. Besser, a hedge fund manager by trade, also serves as the Portfolio Manager for Manchester Management. He became CEO in February 2022, two weeks after the company uplisted to NASDAQ. Manchester Management has led every financing round into Modular Medical for four years. His compensation is primarily equity-based, as he earns a salary of one dollar per year.

Paul DiPerna, Founder + President

Paul DiPerna is the Founder and President of Modular Medical. He brings 30 years of experience in the medical device industry as a technologist, business executive, and founder of several successful startups. His background includes key roles at Baxter Healthcare in product design, manufacturing, business development, and technical diligence on acquisitions. Mr. DiPerna founded Tandem Diabetes Care, where he created the technology and served as CEO and board member, leading to its $450 million IPO in 2013. He also co-invented the Ivera Medical blood-borne infection control device technology, which was successfully acquired by 3M in 2015. In 2015, he founded Modular Medical, which initially was self-funded before merging into a financed public shell in 2017. He holds over 70 patents, predominantly in blood separation technologies, micro pumping, and diabetes care systems. Mr. DiPerna previously served as President and CEO of Modular Medical Inc. from 2015 to 2022.

James Sullivan, Interim Chief Financial Officer

James Sullivan serves as the Interim Chief Financial Officer of Modular Medical, where he oversees the finance and administrative functions. He possesses over 30 years of experience in financial management and accounting, with significant public-company experience across hardware, software, and cloud-services businesses. Mr. Sullivan has completed more than 15 financings in his career. He has held CFO positions at MoSys, Inc., Apptera, Inc., and 8x8, Inc.. Prior to these roles, he worked in the assurance practice at PricewaterhouseCoopers LLP in New York and Silicon Valley. He is a certified public accountant and holds a Bachelor of Science in Accounting from New York University's Stern School of Business.

Kevin Schmid, Chief Operating Officer

Kevin Schmid is the Chief Operating Officer at Modular Medical. He is an accomplished executive with over four decades of specialized expertise in drug delivery and diabetes management. Before joining Modular Medical, Mr. Schmid was the Vice President of Operations and Business Development at Insulet Corporation and also served as the Chief Executive Officer at Common Sensing. He played a key role in building Insulet's first two facilities.

AI Analysis | Feedback

Key Business Risks for Modular Medical (MODD)

Modular Medical, Inc. (MODD), a development-stage medical device company focused on innovative insulin pump technology, faces several critical risks as it progresses toward commercialization. 1. **Regulatory Approval and Commercialization:** As a pre-revenue company, Modular Medical's entire business strategy and ability to generate revenue hinge on the successful and timely clearance of its Pivot tubeless insulin delivery system by regulatory bodies such as the U.S. Food and Drug Administration (FDA). The Pivot system is currently not cleared for sale by the FDA, and while the company aims for a Q1 2026 commercial launch, this is contingent on a favorable regulatory review. A delay in, or failure to obtain, regulatory approval would prevent the company from selling its primary product, critically impacting its financial viability and future prospects. 2. **Competition and Market Adoption:** The insulin pump market is characterized by established "giants" like Medtronic, Insulet, and Tandem Diabetes Care. Modular Medical aims to differentiate its MODD1 product by focusing on simplicity, affordability, and ease of use, targeting a broader segment of insulin-dependent individuals, particularly "almost-pumpers" who currently rely on multiple daily injections due to the perceived complexity or cost of existing pumps. Despite this strategy, there remains a significant risk that Modular Medical's products may not achieve substantial market acceptance or effectively compete against larger, more entrenched players with extensive distribution networks, brand recognition, and potentially more integrated or advanced device ecosystems. 3. **Financing and Dilution:** As a development-stage company with no material commercial revenue, Modular Medical is heavily reliant on equity financing and capital markets to fund its ongoing research, development, regulatory processes, and eventual commercialization efforts. The company has recently engaged in public offerings of common stock and warrants, which introduces a significant risk of share dilution for existing shareholders. A continuous need for capital, coupled with potential difficulties in securing adequate funding on favorable terms or excessive dilution from future offerings, could impede the company's ability to execute its business plan and sustain operations until profitability.

AI Analysis | Feedback

The rapid advancement and increasing adoption of comprehensive automated insulin delivery (AID) or closed-loop systems by established competitors in the diabetes care market. These systems integrate continuous glucose monitors (CGMs) with insulin pumps and sophisticated algorithms to automate insulin delivery, moving beyond standalone pump functionality towards a more "artificial pancreas" experience. As a development-stage company focused on insulin pumps, Modular Medical's ability to compete and gain adoption could be severely hampered if its technology does not seamlessly integrate into or surpass the advanced, integrated solutions offered by industry leaders.

AI Analysis | Feedback

Modular Medical, Inc. (MODD) operates within the broader insulin pump market, with its primary focus on developing and commercializing innovative insulin pumps, including its MODD1 two-part patch pump and the upcoming tubeless Pivot product.

Modular Medical estimates its addressable market for its specific products, targeting individuals who have not yet adopted insulin pumps due to factors like cost and complexity, to be approximately $3 billion. This market is primarily considered for the U.S. initially, with plans for European expansion.

The overall global and U.S. markets for insulin pumps provide a broader context for Modular Medical's operations:

  • The global insulin pump market was valued at approximately USD 7.05 billion in 2025 and is projected to grow to USD 22.45 billion by 2034, exhibiting a compound annual growth rate (CAGR) of 13.41% from 2026 to 2034.
  • In 2025, North America held the largest share of the global insulin pump market, accounting for 57.34%. The North American market was valued at USD 4.04 billion in 2025.
  • The U.S. insulin pump market alone is projected to reach USD 4.51 billion by 2026 and is expected to grow from USD 2,407.3 million in 2024 to USD 3,943.8 million by 2030, at a CAGR of 8.4% from 2025 to 2030.

AI Analysis | Feedback

Here are the expected drivers of future revenue growth for Modular Medical (MODD) over the next 2-3 years:

  1. Commercial Launch and Adoption of the MODD1 Insulin Pump: Modular Medical received FDA 510(k) clearance for its next-generation MODD1 insulin delivery pump. The company anticipates commencing initial shipments of the MODD1 by October 2025, which is a critical step for generating its first significant revenues.
  2. Introduction and Market Penetration of the Pivot Patch Pump: The company has branded a new-generation patch pump as Pivot, with a 510(k) premarket notification submitted to the FDA in November 2025, and a commercial launch projected for the first quarter of 2026, pending regulatory approval. Modular Medical has also successfully validated its Pivot controller manufacturing line, indicating readiness for high-volume production. This product is designed to be a tubeless, removable 3-milliliter patch pump that targets adult "almost-pumpers" who have avoided traditional pumps due to complexity, cumbersomeness, or cost, thus aiming to expand the overall market for insulin pump therapy.
  3. International Market Expansion: Modular Medical intends to pursue regulatory clearances in the European Union, the United Kingdom, Canada, and other international markets. The company plans to conduct academic and usability studies outside the U.S. in preparation for a full commercial launch in these regions. The appointment of a Head of International Operations further underscores this global expansion strategy.
  4. Potential Development and Partnerships for GLP-1 Delivery: Modular Medical is exploring the application of its pump technology for GLP-1 (weight loss/diabetes management) drugs. The company believes this market could be as substantial as its core insulin pump business if successful, and it aims to partner with a drug manufacturer for clearance and marketing in this potential new segment.

AI Analysis | Feedback

Share Issuance

  • Modular Medical completed its Initial Public Offering (IPO) in February 2022, raising $15 million by issuing 2,500,000 shares at $6.00 per share.
  • In February 2024, the company closed a public offering of 9,090,910 shares of common stock at $1.10 per share, generating approximately $10 million in gross proceeds.
  • Modular Medical priced a public offering in March 2026, which is anticipated to generate approximately $12 million in gross proceeds from the sale of common stock and warrants.

Inbound Investments

  • In March 2025, Modular Medical completed a private placement that raised approximately $12 million.
  • Concurrently with the March 2025 private placement, an additional $0.5 million in capital was raised through a direct private placement with a foreign investor.

Capital Expenditures

  • Net property, plant, and equipment increased by approximately $2.84 million from March 2022 to March 2023.
  • The company's net property, plant, and equipment further increased by approximately $0.91 million from March 2023 to March 2024, and by $1.11 million from March 2024 to March 2025.

Peer Outperformance in Life Sciences Tools & Services

MODD has outperformed 51% of its 109 Life Sciences Tools & Services peers over 5Y. Life Sciences Tools & Services ranks 8th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
Share of Life Sciences Tools & Services constituents that MODD has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
1Y
15%
of 125 industry peers · -88.4% return
3Y
19%
of 115 industry peers · -94.2% return
5Y
51%
of 109 industry peers · -75.0% return
No Life Sciences Tools & Services peer with a comparable growth profile has beaten MODD by more than 20pp over 5Y.
Median price return by industry across the Health Care sector, ranked by 5Y. Life Sciences Tools & Services is MODD's own industry. Use this to see which corners of the sector have carried the returns.
Industry Names 1Y med3Y med5Y med Top 3 by 5Y
Health Care Distributors 5 16.4%84.2%198.3% CAH 522% · MCK 400% · COR 198%
Health Care Services 20 31.2%20.2%12.4% RDNT 150% · HIMS 116% · DGX 91%
Managed Health Care 8 76.8%-0.8%0.8% OSCR 155% · HQY 56% · ELV 9%
Health Care Facilities 26 17.8%19.4%-9.2% THC 258% · NHC 231% · EHC 186%
Health Care Equipment 49 -1.7%4.4%-20.2% GKOS 390% · UFPT 359% · TMDX 293%
Health Care Supplies 11 24.0%1.1%-40.5% LNTH 248% · HAE 108% · MMSI 25%
Pharmaceuticals 60 -18.7%1.7%-45.2% LQDA 1123% · KNSA 638% · XERS 586%
Life Sciences Tools & Services ← 110 -22.4%-26.1%-76.2% AXGN 400% · MEDP 187% · NTRA 156%
Health Care Technology 23 -23.5%-59.7%-83.4% VEEV -8% · DOCS -55%
Biotechnology 370 -33.7%-38.5%-83.9% ELVN 1378% · TRVI 1175% · DNTH 1141%
Median of constituents with a full price history over each window. Top names are limited to companies above $2B market cap.

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

MODDPODDTNDMMDTEMBCMedian
NameModular .Insulet Tandem D.MedtronicEmbecta  
Mkt Price1.80144.0017.60102.366.1317.60
Mkt Cap0.010.01.2131.00.41.2
Rev LTM03,1891,07637,5411,0191,076
Op Inc LTM-27588-1017,147248248
FCF LTM-28233-716,132165165
FCF 3Y Avg-22286-745,527104104
CFO LTM-25509-158,035174174
CFO 3Y Avg-20457-67,360116116

Growth & Margins

MODDPODDTNDMMDTEMBCMedian
NameModular .Insulet Tandem D.MedtronicEmbecta  
Rev Chg LTM-26.5%6.8%9.8%-7.6%8.3%
Rev Chg 3Y Avg-27.0%11.8%6.0%-2.9%8.9%
Rev Chg Q-19.2%13.8%13.7%-8.1%13.8%
QoQ Delta Rev Chg LTM-4.4%3.3%3.2%-2.3%3.3%
Op Inc Chg LTM-8.8%34.6%42.9%7.5%-13.6%7.5%
Op Inc Chg 3Y Avg-21.8%66.9%20.5%6.3%1.5%6.3%
Op Mgn LTM-18.4%-9.3%19.0%24.3%18.7%
Op Mgn 3Y Avg-17.1%-17.2%18.5%22.5%17.8%
QoQ Delta Op Mgn LTM-1.5%2.3%0.3%-3.3%0.9%
CFO/Rev LTM-16.0%-1.4%21.4%17.1%16.5%
CFO/Rev 3Y Avg-17.9%-0.5%21.2%10.9%14.4%
FCF/Rev LTM-7.3%-6.6%16.3%16.2%11.7%
FCF/Rev 3Y Avg-11.5%-7.7%15.9%9.8%10.6%

Valuation

MODDPODDTNDMMDTEMBCMedian
NameModular .Insulet Tandem D.MedtronicEmbecta  
Mkt Cap0.010.01.2131.00.41.2
P/S-3.11.13.50.42.1
P/Op Inc-0.517.0-12.218.31.41.4
P/EBIT-0.516.4-33.217.91.61.6
P/E-0.523.3-24.925.04.14.1
P/CFO-0.619.6-83.916.32.12.1
Total Yield-191.4%4.3%-4.1%6.8%31.9%4.3%
Dividend Yield0.0%0.0%0.0%2.8%7.6%0.0%
FCF Yield 3Y Avg-851.7%1.9%-5.9%5.3%22.5%1.9%
D/E0.00.10.60.24.10.2
Net D/E-0.30.00.20.13.50.1

Returns

MODDPODDTNDMMDTEMBCMedian
NameModular .Insulet Tandem D.MedtronicEmbecta  
1M Rtn-22.2%2.1%8.4%8.0%-2.2%2.1%
3M Rtn-40.6%-2.7%-25.8%12.1%20.5%-2.7%
6M Rtn-45.9%-6.9%27.0%32.5%112.6%27.0%
12M Rtn-88.4%-56.1%-4.0%9.8%-55.7%-55.7%
3Y Rtn-94.2%-17.3%-1.1%51.1%-58.6%-17.3%
1M Excs Rtn-9.5%5.0%11.1%13.9%2.3%5.0%
3M Excs Rtn-42.0%-1.2%-21.1%13.4%17.2%-1.2%
6M Excs Rtn-46.8%-7.7%26.1%31.7%111.8%26.1%
12M Excs Rtn-98.9%-66.8%-15.9%0.2%-66.6%-66.6%
3Y Excs Rtn-163.1%-74.5%-46.9%-8.2%-121.3%-74.5%

Comparison Analyses

null

Financials

Segment Financials

Operating Income by Segment
$ Mil2016
Design, development and eventual commercialization of innovative insulin pumps using modernized-0
Total-0


Net Income by Segment
$ Mil202620252024
Design, development and eventual commercialization of innovative insulin pumps using modernized-28-19-17
Total-28-19-17


Assets by Segment
$ Mil20242023202220212020
Design, development and eventual commercialization of innovative insulin pumps using modernized1471024
Total1471024


Price Behavior

Price Behavior
Market Price$1.80 
Market Cap ($ Bil)0.0 
First Trading Date06/25/2009 
Distance from 52W High-88.4% 
   50 Days200 Days
DMA Price$2.07$4.52
DMA Trenddowndown
Distance from DMA-13.2%-60.1%
 3M1YR
Volatility151.2%141.9%
Downside Capture533.72402.97
Upside Capture362.66115.01
Correlation (S&P 500)42.5%25.9%
MODD Betas & Captures as of 10/31/2026

 1M2M3M6M1Y3Y
Beta2.972.250.452.181.791.11
Up Beta-6.51-4.96-3.671.502.090.83
Down Beta-5.91-1.73-0.940.871.351.17
Up Capture716%196%117%198%30%20%
Bmk +ve Days12182862130427
Stock +ve Days8132649103322
Down Capture608%520%270%265%179%112%
Bmk -ve Days10253664121325
Stock -ve Days11263471142396

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MODD
MODD-88.8%141.9%-0.82-
Sector ETF (XLV)24.2%16.9%1.1011.3%
Equity (SPY)10.2%13.8%0.4525.6%
Gold (GLD)-6.3%28.8%-0.2311.2%
Commodities (DBC)31.6%21.3%1.18-14.6%
Real Estate (VNQ)10.0%14.2%0.428.0%
Bitcoin (BTCUSD)-31.4%43.7%-0.7511.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MODD
MODD-56.2%100.6%-0.40-
Sector ETF (XLV)8.6%15.4%0.367.1%
Equity (SPY)10.9%17.3%0.4613.2%
Gold (GLD)15.5%19.2%0.655.8%
Commodities (DBC)7.1%19.6%0.25-3.2%
Real Estate (VNQ)0.9%19.0%-0.069.0%
Bitcoin (BTCUSD)-0.6%51.4%0.176.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with MODD
MODD-33.8%100.6%-0.40-
Sector ETF (XLV)12.4%16.8%0.617.1%
Equity (SPY)14.9%18.0%0.7013.2%
Gold (GLD)11.2%16.6%0.555.8%
Commodities (DBC)7.4%18.2%0.32-3.2%
Real Estate (VNQ)5.8%20.7%0.249.0%
Bitcoin (BTCUSD)57.2%66.3%0.976.4%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date10302026
Short Interest: Shares Quantity0.3 Mil
Short Interest: % Change Since 1015202616.9%
Average Daily Volume0.1 Mil
Days-to-Cover Short Interest3.0 days
Basic Shares Quantity7.9 Mil
Short % of Basic Shares4.1%

Earnings Returns History

Updated 6/2/2026
Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
SUMMARY STATS   
# Positive000
# Negative000
Median Positive   
Median Negative   
Max Positive   
Max Negative   
Collapse to Preview
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
SUMMARY STATS   
# Positive000
# Negative000
Median Positive   
Median Negative   
Max Positive   
Max Negative   

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202611/16/202610-Q
06/30/202608/14/202610-Q
03/31/202606/29/202610-K
12/31/202502/17/202610-Q
09/30/202511/14/202510-Q
06/30/202508/14/202510-Q
03/31/202506/20/202510-K
12/31/202402/13/202510-Q
09/30/202411/14/202410-Q
06/30/202408/13/202410-Q
03/31/202406/21/202410-K
12/31/202302/13/202410-Q
09/30/202311/13/202310-Q
06/30/202308/14/202310-Q
03/31/202306/26/202310-K
12/31/202202/13/202310-Q
Collapse to Preview
Report DateFiling DateFiling
09/30/202611/16/202610-Q
06/30/202608/14/202610-Q
03/31/202606/29/202610-K
12/31/202502/17/202610-Q
09/30/202511/14/202510-Q
06/30/202508/14/202510-Q
03/31/202506/20/202510-K
12/31/202402/13/202510-Q
09/30/202411/14/202410-Q
06/30/202408/13/202410-Q
03/31/202406/21/202410-K
12/31/202302/13/202410-Q
09/30/202311/13/202310-Q
06/30/202308/14/202310-Q
03/31/202306/26/202310-K
12/31/202202/13/202310-Q
09/30/202211/14/202210-Q
06/30/202208/11/202210-Q
03/31/202206/28/202210-K
12/31/202102/14/202210-Q
09/30/202111/12/202110-Q
06/30/202108/16/202110-Q
03/31/202106/29/202110-K
12/31/202002/12/202110-Q
09/30/202011/09/202010-Q
06/30/202008/12/202010-Q
03/31/202006/29/202010-K
12/31/201902/13/202010-Q
Core Cache Last Updated: 11/17/2026